Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2026-04-26 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
2025年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled "2025年度内部控制自我评价报告" which translates to "2025 Internal Control Self-Evaluation Report". It discusses the company's internal control evaluation for the fiscal year ending December 31, 2025. The content includes detailed descriptions of internal control environment, risk assessment, control activities, information and communication, and internal supervision. It also includes standards for identifying internal control deficiencies and the company's conclusions on the effectiveness of internal controls. There is no indication that this is an announcement of a report publication or a brief summary. The document is comprehensive and contains substantive information about internal controls, which aligns with an Audit Report / Information filing rather than a full Annual Report or other categories. Therefore, the document fits best under the Audit Report / Information (AR) category. FY 2025
2026-04-26 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '恩威医药股份有限公司2026年第一季度报告' which translates to 'Enwei Pharmaceutical Co., Ltd. 2026 First Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes on financial indicators for the first quarter of 2026. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It also mentions that the report is unaudited. There is no indication that this is an announcement of a report or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-26 Chinese
2025年年度报告
Annual Report Classification · 100% confidence The document is titled "惠威医药股份有限公司2025年年度报告全文" which translates to "Enwei Pharmaceutical Co., Ltd 2025 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, and financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial data, management statements, and detailed business and industry analysis. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-04-26 Chinese
关于控股股东、持股5%以上股东部分股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the release of pledged shares by major shareholders (controlling shareholder and shareholders holding more than 5%) of the company. It details the number of shares released from pledge, the shareholders involved, and the impact on the company. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledge status and changes, which fits the category of Major Shareholding Notification (MRQ) as it involves significant shareholders and their share pledges. The document length is short and focused on shareholding changes, not a full report or financial statement.
2026-04-21 Chinese
关于控股股东、持股5%以上股东部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the pledge of shares by controlling and significant shareholders (those holding more than 5% of shares) of the company. It details the number of shares pledged, the proportion of total shares, the pledge terms, and assurances about the impact on the company. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about shareholder share pledges, which fits the category of Regulatory Filings (RNS) as it does not fit into more specific categories like Capital/Financing Update (CAP) because it is about share pledges by shareholders rather than company capital changes or fundraising. The document length is short (3009 characters), and it is a direct announcement, not a report publication notice. Therefore, the best classification is Regulatory Filings (RNS).
2026-04-16 Chinese
关于2023年限制性股票激励计划第二个归属期第二批次归属结果暨股份上市的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the 2023 restricted stock incentive plan of Enwei Pharmaceutical Co., Ltd., specifically about the second vesting period's second batch of restricted stock vesting results and the listing of shares. It includes extensive information on the stock incentive plan, vesting conditions, approval procedures, stock quantities, prices, legal opinions, and the impact on the company's shareholding structure. The document is lengthy (15,000 characters) and contains substantive details about the stock incentive plan implementation and vesting results, not merely an announcement of a report or a brief summary. It is not a full annual or interim financial report, nor an earnings release or call transcript. It is a regulatory announcement about stock incentive plan vesting and share listing, which fits best under the category of Regulatory Filings (RNS) because it is a regulatory disclosure about share-based compensation and related corporate actions, but does not fit into more specific categories like Capital/Financing Update or Director's Dealing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-04-10 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.